



For further information please contact:

ANTISENSE PHARMA GmbH
Dr. Heike Specht / Public Relations
Josef-Engert-Str. 9, D-93053 Regensburg
Phone: +49-941-92013-0
Fax: +49-941-92013-29
e-mail: pr@antisense-pharma.com
www.antisense-pharma.com

Press Release

Antisense Pharma GmbH welcomes Hubert Heinrichs to the Executive Board

Regensburg, Germany, November 21st, 2006 - Antisense Pharma, a German biopharmaceutical company developing targeted therapies for malignant tumors, announced the appointment of Hubert Heinrichs, M.D., to its executive board. Hubert Heinrichs, with a strong background and vast experience in the pharmaceutical industry, especially in drug approvals, joins the founders Karl-Hermann Schlingensiepen and Reimar Schlingensiepen, expanding the executive board to three members.

Hubert Heinrichs joined Antisense Pharma in January 2006 as Chief Medical Officer. He brings to the company over 15 years of pharmaceutical industry experience related to the complex needs of the clinical development and regulatory approval process in Europe, the U.S. and Japan. Prior to joining Antisense Pharma, Hubert Heinrichs, M.D. was Head of Clinical Research and Development at Aventis Behring/ZLB Behring.

In his capacity as Chief Medical Officer of Antisense Pharma, his primary goal is to make the company's lead product - AP 12009 - available to patients with malignant tumors, offering them a therapeutic alternative. "I am very excited about the prospect of mastering this task, together with the founders and our highly committed team", said Heinrichs. "Cancer therapies targeting TGF-beta have an excellent potential and offer the promise of a better future for patients with malignant tumors."

The prime focus of the executive board is to strengthen Antisense Pharma's leading position in the field. "Strategic competence, an experienced team of professionals and the highest quality standards will secure our long-term success", commented Heinrichs.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. The lead product AP 12009 is currently in clinical development for glioma, colorectal carcinoma, pancreatic carcinoma and malignant melanoma. The further product pipeline comprises drugs for the treatment of lung carcinoma, prostate carcinoma and other neoplasms which are currently in advanced stages of preclinical development. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.

This document contains forward-looking statements with respect to the future business of Antisense Pharma GmbH. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that could occur in the future. There is a number of factors that could cause actual results and developments to differ materially. Antisense Pharma GmbH disclaims any intent of obligation to update any of these forward-looking statements.

[Press Release November 21st 2006](#)

[Photography is available in support of this release, see contact information above.](#)